AU2702795A - Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration - Google Patents

Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration

Info

Publication number
AU2702795A
AU2702795A AU27027/95A AU2702795A AU2702795A AU 2702795 A AU2702795 A AU 2702795A AU 27027/95 A AU27027/95 A AU 27027/95A AU 2702795 A AU2702795 A AU 2702795A AU 2702795 A AU2702795 A AU 2702795A
Authority
AU
Australia
Prior art keywords
solid
nicotine
xanthine
caffeine
semi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27027/95A
Inventor
Satyanarayana Majeti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU2702795A publication Critical patent/AU2702795A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU27027/95A 1994-06-23 1995-06-09 Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration Abandoned AU2702795A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26466694A 1994-06-23 1994-06-23
PCT/US1995/007380 WO1996000069A1 (en) 1994-06-23 1995-06-09 Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
US264666 2002-10-04

Publications (1)

Publication Number Publication Date
AU2702795A true AU2702795A (en) 1996-01-19

Family

ID=23007084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27027/95A Abandoned AU2702795A (en) 1994-06-23 1995-06-09 Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration

Country Status (6)

Country Link
AU (1) AU2702795A (en)
IL (1) IL114130A0 (en)
MA (1) MA23586A1 (en)
PE (1) PE39996A1 (en)
WO (1) WO1996000069A1 (en)
ZA (1) ZA955033B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2340397A (en) * 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
AUPO108596A0 (en) * 1996-07-18 1996-08-08 Collier, Gregory Treatment of obesity
CA2325106A1 (en) * 1999-12-06 2001-06-06 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778677A (en) * 1981-07-09 1988-10-18 Ebbesen Gerald K Method for treatment of nicotine craving
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
DE3506406A1 (en) * 1985-02-23 1986-08-28 Hans-Josef 5600 Wuppertal Stromberg DEVICE FOR THE DEWNING OF EATING, DRINKING, SMOKING AND / OR ADDICTIVE Habits
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4959380A (en) * 1988-12-19 1990-09-25 Wilson Jordan E Method of treating people to stop smoking and composition
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency

Also Published As

Publication number Publication date
IL114130A0 (en) 1995-10-31
ZA955033B (en) 1996-02-15
WO1996000069A1 (en) 1996-01-04
PE39996A1 (en) 1996-10-03
MA23586A1 (en) 1995-12-31

Similar Documents

Publication Publication Date Title
AU2703795A (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
CA2127253A1 (en) Composition to help stop smoking
AU2770895A (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with an oral composition containing nicotine and caffeine or xanthine
EP0296236A4 (en) Nasal delivery of caffeine.
AU5015385A (en) Tobacco compositions, method and device for releasing essentially pure nicotine
CA2084771A1 (en) Nicotine-impermeable container and method of fabricating the same
CA2146954A1 (en) Breath activated nicotine inhalers
GB9312853D0 (en) Chemical compounds
NO963322L (en) Procedure for the treatment of abstinence in substance abuse
EP0824927A3 (en) Smoke cessation aid
AU2703695A (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a liquid nasal composition containing nicotine and caffeine or xanthine
AU2702795A (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
EP1078637A3 (en) Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug
AU6528400A (en) Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
GB2219587B (en) Nitrogen-containing derivatives of carboxymethylcellulose,their preparation and their luse in cosmetic formulations
EP0745380A3 (en) Tobacco substitute
WO1996005836A3 (en) Methods of treating cold symptoms using pentoxifylline
AU4476089A (en) Use of azepinone derivatives for the treatment of respiratory tract disorders
WO1996036324A3 (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
Sherwood et al. No differences in the psychomotor response of heavy, light and non-smokers to the acute administration of nicotine.
AU8096094A (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
NO943293L (en) Use of a drug in the treatment of smoking
AU2446895A (en) Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
AU1777988A (en) Tobacco product for the personal preparation of a cigarette, in particular filter cigarette
GB9410482D0 (en) Tobacco smokers' mouthpiece